Pharmaceutical

CD70 CAR-T by UTC Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.

Aug 10, 2023 - 20:00
CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.
Read the original article

Tags:

Previous Article

CD70 CAR-T by UTC Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): ...

Next Article

CD70 CAR-T by UTC Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likeli...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Lumen Bioscience’s LMN-201 secures FDA fast track statu...

May 18, 2023

Signal: PureHealth UK expansion shows continued focus on healthcare in UAE

Signal: PureHealth UK expansion shows continued focus o...

Aug 30, 2023

Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests

Niacin has long been a public health darling. But an ex...

Feb 19, 2024